Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition (Q34015968)

30 July 2017

title

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition (English)

1 reference

30 July 2017

0 references

1 reference

8

Hannele Yki-Järvinen

1 reference

30 July 2017

6

Robert J Heine

1 reference

30 July 2017

Marja-Riitta Taskinen

7

object named as

Marja-Riitta Taskinen

1 reference

30 July 2017

2

Michaela Diamant

1 reference

30 July 2017

Mathijs C Bunck

1

1 reference

30 July 2017

Bjorn Eliasson

3

1 reference

30 July 2017

Anja Cornér

4

1 reference

30 July 2017

Rimma M Shaginian

5

1 reference

30 July 2017

Ulf Smith

9

1 reference

30 July 2017

language of work or name

English

0 references

publication date

27 April 2010

1 reference

30 July 2017

1 reference

30 July 2017

volume

33

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

1734-1737

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

30 July 2017

copyright license

start time

1 September 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

The role of incretins in glucose homeostasis and diabetes treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Role of body fat distribution and the metabolic complications of obesity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Incretin mimetics as a novel therapeutic option for hepatic steatosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Exendin-4 potently decreases ghrelin levels in fasting rats.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909051

Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20424219

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DC09-2361

1 reference

30 July 2017

1 reference

30 July 2017

1 reference